Matrixyl: what the evidence shows

What the human research shows

Twelve weeks, 93 people, split-face design, vehicle control, two independent measurement methods — methodologically the strongest cosmetic-peptide trial on this site, and funded and run by the company that sells it. Graded C: one industry trial with a modest effect is evidence, not establishment.

Evidence profile0–5

Metabolic & weight—0.0
Cardiovascular—0.0
Muscle & growth—0.0
Healing & repair—0.0
Neuro & sleep—0.0
Immune & inflammation—0.0
Sexual & hormonal—0.0
Skin & appearance—0.0
Ageing & longevity—0.0

No benefit outcome for Matrixyl has both human evidence and a measurable effect, so the profile is empty. That is the finding, not a gap in the chart.

Outcome	Grade	Effect size	Human studies	Where the evidence comes from
Wrinkles and fine lines (topical)	CWeak	Small	1 split-face RCT (n=93, 12 wk)	A 12-week double-blind split-face study in 93 women aged 35–55 applied 3 ppm pal-KTTKS in a moisturiser to one side of the face and vehicle to the other. Both quantitative image analysis and expert graders found significant improvement in wrinkles and fine lines on the treated side. Split-face design controls for the person; it does not control for the sponsor, which developed and sells the ingredient.1
Collagen synthesis	DNo human evidence	Not measurable	None in vivo	The mechanism rests on fibroblast culture work showing that KTTKS stimulates collagen I, collagen III and fibronectin production. No human study has measured collagen synthesis in skin after topical pal-KTTKS.
Safety (topical)adverse	CWeak	Not measurable	1 RCT (n=93, 12 wk)	The trial reported the peptide was well tolerated by the skin over twelve weeks. Decades of cosmetic use at parts-per-million concentrations have produced no safety signal.1

AMultiple good human trials, consistentBSome human trials, mostly consistentCFew or weak human studiesDAnimal or anecdotal onlyeffect size · red = adverse

Literature searched to 29 October 2026. Human studies only; animal and cell work informs the mechanism section and nothing else.

What it is

KTTKS (Lys-Thr-Thr-Lys-Ser) is a fragment released when type I procollagen is processed, and in cell culture it feeds back on fibroblasts to stimulate collagen production. On its own it does not get through skin, so a 16-carbon palmitic acid chain was attached to the N-terminus; that lipid tail is what makes pal-KTTKS deliverable in a cream. The ingredient dates from the 1990s and is used at a few parts per million.

"Matrixyl 3000" and "Matrixyl synthe'6" are different products from the same supplier containing different peptides — palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 in the former. The trial on this page tested pal-KTTKS alone, and does not transfer to those blends.

How it is thought to work

A matrikine: a peptide released by collagen breakdown that signals the matrix needs rebuilding. In fibroblast culture KTTKS raises collagen I, collagen III and fibronectin synthesis. The palmitoyl tail provides skin penetration. Whether the measured wrinkle changes come from that signalling pathway, from the barrier effects of the lipid, or from the moisturiser carrying it, the trial cannot say.

What is still unknown

Whether the effect is the peptide or its lipid tail and vehicle — no trial has separated them.
Whether topical application changes collagen in human skin, as opposed to appearance measures.
Whether the result replicates outside the sponsor's laboratory; no independent trial exists.

The molecule and how long it lasts

Identity

Formula: C39H75N7O10
Molecular weight: 802.1 g/mol
CAS number: 214047-00-4
PubChem: CID 9897237
Sequence: Pal-KTTKS

PubChem record, read 29 October 2026; the sequence was derived from that record's own structure and checked against the product label where one exists.

Pharmacokinetics

Route: Topical (cosmetic serum or cream)
Half-life: No human pharmacokinetic study; the palmitoyl tail is added to aid skin penetration, which has not been quantified in people

No pharmacokinetic study in people.

Regulatory status

European Union

Cosmetic ingredient

Lawful in cosmetics. No authorised health claim.

United States

Cosmetic ingredient

Sold in cosmetics without pre-market approval; not an approved drug.

United Kingdom

Cosmetic ingredient

Lawful in cosmetics under the UK Cosmetics Regulation.

Australia

Cosmetic ingredient

Topical cosmetic use is not regulated as a medicine.

Canada

Cosmetic ingredient

Permitted in cosmetics; subject to cosmetic notification.

Sport (WADA)

Not named

Not on the Prohibited List.

Questions people actually ask

Is Matrixyl better evidenced than argireline?

Methodologically yes: twelve weeks against four, 93 people against 60, split-face control, and two independent measurement methods. Both rest on a single industry-run trial, so both are graded C.

Is Matrixyl 3000 the same thing?

No. Matrixyl 3000 is a different blend containing palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. The trial described here tested pal-KTTKS on its own.

Does Matrixyl build collagen in skin?

That is the mechanism proposed from fibroblast culture. No human study has measured collagen in skin after applying it — the trial measured how the skin looked, not what it contained.

One page per claimed effect

CDoes Matrixyl help with wrinkles and fine lines?1 split-face RCT (n=93, 12 wk)
DDoes Matrixyl help with collagen synthesis?None in vivo
CHow common is safety with Matrixyl?1 RCT (n=93, 12 wk)

References

1
Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin.Int J Cosmet Sci, 2005;27:155–16093 women aged 35–55; 12-week double-blind split-face study of 3 ppm pal-KTTKS versus vehicle. Procter & Gamble authors.
2
PubChem compound record: palmitoyl pentapeptide-4.PubChem, read 29 Oct 2026Formula, molecular weight, CAS and the Pal-KTTKS sequence used on this page.

Change log

2026-10-29Initial publication. Grade C on one industry-run split-face trial.